Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Colon cancer; rectal cancer Clinical Trials

A listing of Colon cancer; rectal cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (51) clinical trials

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Randomized studies have demonstrated that Tas-102 has single agent activity against chemotherapy refractory colorectal cancer. A recent pre-clinical study has shown that Tas-102 may have activity as a radiation sensitizer in bladder cancer cell lines. Benefit of single agent Tas-102 against chemotherapy refractory colon cancer and the drug's promise a ...

Phase

Natural Killer Cells and Bortezomib to Treat Cancer

Natural killer (NK) cells are innate immune lymphocytes that are identified by the expression of the CD56 surface antigen and the lack of CD3. Unlike antigen specific T cells, NK cells do not require the presence of a specific tumor antigen for the recognition and killing of cancer cells. Our ...

Phase

Oral STAT3 Inhibitor TTI-101 in Patients With Advanced Cancers

Signal transducer and activator of transcription 3 (STAT3) is a member of a family of seven closely related proteins responsible for transmission of peptide hormone signals from the extracellular surface of cells to the nucleus. STAT3 is a master regulator of most key hallmarks and enablers of cancer, including cell ...

Phase

Trametinib and TAS-102 in Treating Patients With Colon or Rectal Cancer That is Advanced Metastatic or Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) for the combination of trametinib and trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) in patients with chemotherapy-resistant metastatic colorectal cancer. SECONDARY OBJECTIVES: I. Describe the safety of the combination of trametinib and TAS-102 across all investigated dose levels. II. Describe the clinical ...

Phase

A Study of XmAb 20717 in Subjects With Selected Advanced Solid Tumors

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

Phase

FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: Regimen A: FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies. Regimen B: FATE-NK100 in combination with trastuzumab in subjects with human epidermal ...

Phase

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Study Design: This open label, multicenter, first-in-human study consists of 2 parts. Part 1 is a dose escalation to find the recommended Phase II dose (RP2D) of MCLA-158 studying patients with metastatic colorectal cancer. Part 2 is a dose expansion cohort studying MCLA-158 in colorectal cancer and other solid tumor ...

Phase

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Dose escalation of AB928 in combination with AB122 will be assessed in participants with advanced malignancies. In this dose escalation combination study participants will receive oral administration of AB928 as well as iv infusion of AB122. Overall duration of treatment will depend on how well the treatment is tolerated. Treatment ...

Phase

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of CPI-613 (6,8-bis[benzylthio]octanoic acid), when used in combination with 5-FU (fluorouracil), in patients with non-resectable metastatic colorectal cancer who have failed FOLFOX (leucovorin calcium, fluorouracil and oxaliplatin), FOLFIRI (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) and, if Kirsten rat sarcoma viral ...

Phase

Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

There are two common combinations of chemotherapy drugs used to treat cancer of the colon, rectum, or appendix that has spread to the abdomen. One uses 5-fluorouracil (also called 5-FU), leucovorin and oxaliplatin, and is called FOLFOX. The other uses 5-FU, leucovorin, and irinotecan, and is called FOLFIRI. The Food ...

Phase